Inclisiran be sold by retail under prescription of cardiologist only: CDSCO panel tells Novartis Healthcare
New Delhi: Rejecting the drug major Novartis Healthcare's proposal for amendment in the warning statement of Inclisiran Solution for injection, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has stated that the drug Inclisiran Solution for injection should be prescribed with a warning statement as ‘To be sold by retail under the prescription of a cardiologist only’.
This came after Novartis Healthcare presented the proposal for amendment in the warning statement of permission granted to import and market Inclisiran Solution for injection before the committee.
Inclisiran is a medication that reduces levels of low-density lipoprotein (LDL) cholesterol, also known as "bad cholesterol." It's used to treat: High LDL cholesterol, atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia.
Inclisiran is a synthetic, double-stranded RNA (siRNA) molecule that's injected subcutaneously. It's taken up by the liver cells. It binds to and degrades PCSK9 mRNA, which reduces the production of PCSK9 protein. This reduces the amount of LDL cholesterol in the blood.
At the recent SEC meeting for Cardiovascular held on 6th November 2024, the expert panel reviewed the proposal for amendment in the warning statement of permission granted to import and market Inclisiran Solution for injection
After detailed deliberation, the committee did not recommend the amendment in the warning statement.
Furthermore, the expert panel added that the drug Inclisiran solution for injection should be prescribed with a warning statement as follows:
‘To be sold by retail under the prescription of cardiologist only’.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.